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Abstract
Recent trends in prescriptions for medicines used to treat chronic obstructive pulmonary disease 
(COPD) in the United States have received little attention. Our objective was to examine trends in 
prescribing practices for medications used to treat COPD. We examined data from surveys of 
national samples of office visits to non-federal employed office-based physicians in the United 
States by patients aged ≥40 years with COPD recorded by the National Ambulatory Medical Care 
Survey from 1999 to 2010. From three diagnostic codes, office visits by patients with COPD were 
identified. Prescribed medications were identified from up to 8 recorded medications. The 
percentage of these visits during which a prescription for any medication used to treat COPD was 
issued increased from 27.0% in 1999 to 49.1% in 2010 (p trend < 0.001). Strong increases were 
noted for short-acting beta-2 agonists (17.6% in 1999 to 24.7% in 2010; p trend < 0.001), long-
acting beta-2 agonists as single agents or combination products (6.2% in 1999 to 28.3% in 2010; p 
trend < 0.001), inhaled corticosteroids as single agents or combination products (10.9% in 1999 to 
30.9% in 2010; p trend < 0.001), and tiotropium (3.8% in 2004 to 17.2% in 2010; p trend < 0.001). 
Since 1999, prescription patterns for medicines used to treat COPD have changed profoundly in 
the United States.
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Chronic obstructive pulmonary disease (COPD) continues to be a substantial source of 
morbidity and mortality in the United States (1, 2). This disease, which is largely caused by 
noxious pulmonary irritants, is often progressive in nature and is characterized by a largely 
irreversible airway obstruction and an inflammatory component. Although the clinical 
course is variable, many patients experience a progressive loss of pulmonary function that 
may be a consequence of continued exposure to harmful agents as well as exacerbations of 
their condition. As the disease progresses, some patients may experience hypoxia 
necessitating the use of oxygen. Consequently, patients with COPD experience impaired 
health-related quality of life, excess outpatient visits, visits to the emergency room, and 
hospitalizations. The ultimate toll of this disease manifests itself in an elevated mortality 
rate.
Several decades ago, treatment options for COPD were limited and consisted chiefly of 
agents that led to the short-term alleviation of symptoms. Over time, however, the 
therapeutic arsenal at the disposition of physicians has broadened considerably especially 
with the advent of longer-acting inhaled beta-adrenergic agents, anticholinergic agents, and 
corticosteroids. Clinical trials have generated evidence of the usefulness of these longer-
term medications, which have generally provided superior treatment of symptoms, reduced 
exacerbations, reduced mortality, and possibly reduced the loss of lung function (3–7). As a 
result of these developments, professional societies and international organizations have 
developed and periodically adapted treatment guidelines for COPD (8–11).
In light of this evolution in treatment paradigms for COPD, an understanding of how 
treatment practices by the medical community in the United States continue to evolve is 
valuable in gauging the impact of treatment guidelines and generating insights as to whether 
efforts to speed the translation of clinical guidelines into real world practice are possibly 
needed. Yet, little such information is available. To examine recent patterns in the 
pharmacologic treatment of patients with COPD, we examined trends in prescribed 
medications used to treat COPD among adults in the United States from 1999 to 2010 using 
an annual national survey of office visits implemented by the Centers for Disease Control 
and Prevention (CDC).
Methods
Our analyses were conducted using data from the National Ambulatory Medical Care 
Survey (NAMCS) from 1999 to 2010. Using a multistage sampling design, NAMCS is 
intended to provide national estimates about the use of ambulatory medical care services in 
the United States. For each year, a national probability sample of nonfederally employed 
office-based physicians, and, since 2006, of physicians working in Community Health 
Centers was selected. Master files of the American Medical Association (AMA) or the 
American Osteopathic Association (AOA) were used to construct the sampling frame for 
nonfederally employed office-based physicians, whereas information from the Health 
Resources Administration and the Indian Health Service was used to construct the sampling 
frame for physicians working in Community Health Centers. The various stages of selection 
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included primary sampling units (PSUs) (counties, county equivalents (such as parishes and 
independent cities), towns, townships, minor civil divisions), physician practices within 
PSUs, and patient visits within practices. For that final stage of selection, physicians 
selected a systematic random sample of patient visits during an assigned week. Data 
collection is performed by physicians, their staff, and field representatives of the U.S. 
Census Bureau. An important consideration about NAMCS is that each data record on the 
data set contains information about the patient-physician encounter or visit. Thus, NAMCS 
yields estimates about patient-physician encounters or visits rather than patients per se as the 
former constitutes the basic sampling unit of the survey. To generate national estimates of 
the use of ambulatory medical care services, sampling weights were constructed based on 
the following steps: inflation of reciprocals by sampling probabilities, adjustment for 
nonresponse, ratio adjustment, and weight smoothing. Detailed information about the survey 
can be found elsewhere (12).
Using three data fields that contained International Classification of Diseases (ICD)-9 codes 
for the physician’s diagnosis, we defined COPD if any of the fields contained one of the 
following ICD-9 codes: 490, 491, 492, and 496. The surveys contained 6 data fields for 
recording medications from 1999 to 2002 and 8 such fields from 2003 to 2010. Using the 
classification system of drugs by entry name developed by the National Center for Health 
Statistics, we identified medications used in the treatment of COPD and created several 
groups of medications (Table 1). We counted two combinations of medications (albuterol 
and atropine; albuterol and cromolyn) that were prescribed infrequently as albuterol. For 
some medication entries for the above corticosteroids that did not list a brand name, we 
counted the steroid when one of the three reasons for the office visit listed one or more of 
the following: shortness of breath; labored or difficult breathing (dyspnea); wheezing; 
breathing problems; cough; excessive sputum; bronchitis; emphysema; or other respiratory 
diseases (includes COPD). We did not include codes that indicated various nonspecific 
codes for bronchodilator, inhaler, nebulizer, beta agonist, metered dose inhaler, aerosol 
therapy, and asthma medication.
We examined trends in prescriptions by presence or absence of respiratory symptoms that 
were included on one of the three data fields listing reasons for the office visit and included 
shortness of breath, labored or difficult breathing (dyspnea), wheezing, breathing problems, 
cough, and excessive sputum. To improve the stability of the estimates for these analyses, 
we grouped survey years into 4-year blocks: 1999–2002, 2003–2006, and 2007–2010.
We limited our analyses to patients who were aged ≥40 years. Because the physician-patient 
encounter or visit constitutes the unit of analyses, our estimates represent the percentage of 
visits made by patients for whom a diagnostic code for COPD was recorded and who were 
prescribed the medications of interest among all physician-patient encounters or visits that 
listed a diagnostic code for COPD. Linear trends in the percentages of these office visits 
during which patients were prescribed medications used to treat COPD were tested by using 
orthogonal polynomial contrasts. Then, t-tests were used to perform two sample tests of 
significance. Sampling weights were used to generate percentages. The statistical software 
programs SUDAAN (Release 11.0.0) and SAS (version 9.3) were used to conduct the 
analyses.
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From 1999 to 2010, the raw number of office visits by patients with a diagnosis of COPD on 
the data files ranged from 277 to 456 representing an estimated annual number of visits in 
the United States ranging from 11,867,000 to 21,358,000 after weighting. Mean age 
increased significantly over this time, whereas the percentages of visits for COPD by men 
and whites showed no significant linear trends (Table 2).
Overall trends
Short-acting agents were commonly prescribed medications to patients with COPD, and the 
percentage of office visits during which one of these agents was prescribed increased 
strongly from 23.8% in 1999 to 31.9% in 2010 (p linear trend < 0.001) (Table 3, Figure 1). 
Short-acting beta-2 agonists (SABA) were the most commonly prescribed short-acting 
medication, and the percentage of office visits by patients with COPD that were 
characterized by a prescription for a SABA increased significantly from 17.6% in 1999 to 
24.7% in 2010 (plinear trend < 0.001). The combination of a SABA and ipratropium was the 
next most commonly prescribed medication. From 1999 to 2004, the percentage of patients 
being prescribed such combination products increased to 10.6%, then dropped off to 8.9% 
by 2005, and remained relatively unchanged though 2010. Generally, fewer than 6% of 
patients received prescriptions for ipratropium (except in 2004) and methylxanthines. From 
2001 on, prescriptions for ipratropium ( = 0.008) and methylxanthines (p = 0.001) were 
generally in a downward trend.
We examined the Food and Drug Administration’s online drug database for year of approval 
of medications used in this analysis to provide temporal context for the trends in 
medications, particularly long-acting medications. For the major classes, the agents that 
were first approved included metaproterenol in 1974 (SABA), salmeterol in 1994 (LABA), 
ipratropium in 1986 (anti-cholinergics), aminophylline in 1940 (methylxanthines), 
beclomethasone in 1986 (ICS), albuterol/ipratropium in 1996 (SABA plus anticholinergic), 
and salmeterol/fluticasone in 2000 (LABA plus ICS). Prescriptions for long-acting agents 
increased strongly during the study period: the percentage of office visits during which a 
prescription for such an agent was issued more than tripled from 11.8% in 1999 to 37.2% in 
2010 (p linear trend < 0.001) (Table 3, Figure 1).
Combination products were the most commonly prescribed medication followed by 
tiotropium. Both classes of medications showed strong increases since they were approved 
by the Food and Drug Administration (salmeterol plus fluticasone in 2000; tiotropium in 
2004) (p linear trend <0.001 for both). The percentage of office visits with a diagnosis of 
COPD during which a combination product containing a long-acting beta-2 agonists 
(LABA) and an inhaled corticosteroid (ICS) were prescribed increased from 6.2% in 2001 to 
26.7% in 2010 (p linear trend <0.001), Furthermore, the percentage of office visits with a 
diagnosis of COPD during which tiotropium was prescribed increased from 6.3% in 2005 to 
17.2% in 2010 (p linear trend <0.001). In contrast, prescriptions for LABAs as single agents 
and ICS as single agents decreased significantly during the same period (p linear trend 
<0.001 for both).
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Excluding patient visits listing asthma (ICD-9 code 493) on one of the three diagnosis fields 
had little effect on the results (Table 4).
Respiratory symptoms and prescribed medications
The percentage of office visits with a recorded reason for visit of respiratory symptoms 
ranged from a low of 34.4% in 2007 to a high of 49.7% in 2002 (Figure 2). In general, 
medications were as likely to be prescribed during office visits that listed respiratory 
symptoms as one of the reasons for the office visit as during office visits that did not (Table 
5). For both patients with and without respiratory symptoms, significant increases in the 
percentage of office visits by patients with a diagnosis of COPD who were prescribed a 
medication of interest were noted for SABA, LABA plus ICS, any LABA, any ICS, 
tiotropium, any long-acting medication, and any medication.
Discussion
Our analyses of trends in prescribing practices show that the period from 1999 to 2010 was a 
dynamic time that saw large shifts in prescribing practices for patients with COPD. 
Prescriptions for SABAs, combinations of LABAs and ICSs, and tiotropium increased 
steadily whereas prescriptions for ipratropium, methylxanthines, LABAs as single agents, 
and ICSs as single agents decreased. Although at the onset of the study period short-acting 
agents were prescribed more frequently than long-acting agents, by the end of the study 
period long-acting agents were prescribed about as often as short-acting agents. In 2010, 
approximately 50% of patients with COPD walked out of the office with a prescription for a 
COPD medication.
Limited research has examined trends in prescribing practices for medications used in the 
treatment of COPD in the United States. In an analysis of data from 1995 to 2004, 
prescriptions for oral corticosteroids in men and methylxanthines in men and women 
decreased but prescriptions for anticholinergic agents increased (13).
Prior to 2000, mostly short-acting agents were available to treat COPD including SABAs, 
ipratropium, and methylxanthines. Longer acting agents included salmeterol, approved by 
the Food and Drug Administration in 1994, and ICS. Starting in 2000, long-acting 
therapeutic options increased with the approval of the combination of salmeterol and 
fluticasone in 2000, formoterol in 2001, tiotropium in 2004, arformoterol in 2006, and the 
combinations of formoterol and budesonide in 2006. Subsequently, tiotropium and 
medications containing combinations of LABAs and ICS enjoyed strong growth in 
prescriptions. The sizeable jump in LABAs and ICSs in 2010 should be cautiously 
interpreted as there can be considerable year-to-year variation in prescriptions for some 
classes of medications. The rates of increase in the percentage of office visits by patients 
with COPD during which a prescription for major groups of medications used to treat COPD 
was issued were reasonably similar as suggested by Figure 1.
Guidelines for the pharmacologic treatment of COPD have evolved as new medications 
were developed and approved and more has been learned about the benefits and harms of 
various therapeutic options. During the study period from 1999 to 2010, various guidelines 
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that contained recommendations for the pharmacologic treatment of patients with COPD 
were released that may have influenced practice patterns (8, 9, 14–20). In the 1995 
guidelines from the American Thoracic Society, long-acting beta-2 agonists were not 
discussed and the use of inhaled corticosteroids received little attention (8). 
Recommendations regarding pharmacologic treatment were largely limited to short-acting 
anticholinergic agents and short-acting beta2-agonists. In the initial release of the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in 2001, short-acting 
bronchodilators were recommended for regular treatment of patients with mild COPD, one 
or more bronchodilators were recommended for regular treatment of those with moderate 
COPD, and one or more bronchodilators were recommended for regular treatment of those 
with severe COPD along with the use of inhaled corticosteroids in the presence of 
significant respiratory symptoms, lung function response, or repeated exacerbations (14).
Our findings suggest that the recommendations from American College of Physicians, 
American College of Chest Physicians, American Thoracic Society, and European 
Respiratory Society (ACP/ACCP/ATS/ERS) and the Global Initiative for Chronic 
Obstructive Lung Disease are progressively being adopted. However, we were unable to 
establish how well the guidelines were being implemented in clinical practice because the 
guidelines incorporate the presence of respiratory symptoms and results from pulmonary 
function testing, and results from pulmonary function testing were not available in the data 
sets. Possibly, the development, introduction, and promotion of new medications, 
advertising of medications used to treat COPD to the public, continuing medical education, 
and evolving education of medical students may also have influenced prescribing practices.
The findings of the present study are subject to several limitations. First, sample size, 
although fair, was nevertheless too small to allow stratification by various covariates by 
single year. This necessitated pooling of data for several years. Second, because the unit of 
analysis was an office visit not an individual patient, it is possible that a patient could have 
been resampled. Third, results from spirometry even if performed were not available, and, 
therefore, we were unable to stratify patients by severity of their disease. Fourth, we were 
unable to assess whether patients were being inappropriately treated because to do so would 
require a comprehensive review of prescriptions received by patients or perhaps information 
directly obtained from patients about the medications they use. Because the sampling unit of 
NAMCS is the patient-physician encounter or visit at a single point of time, the survey does 
not provide information about the use of all medications at the patient level.
It is tempting to speculate that some of the observed trends in prescribing practices such as 
the increasing trend for medications that combine a LABA and an ICS have translated into 
improved care for patients with COPD. However, the NAMCS surveys are not designed to 
examine the question of whether the evolution in prescribing practices lead to improvements 
in care for patients with COPD. To adequately address the issue of improved care would 
require quite different studies. In addition, studies that have information about the presence 
of respiratory symptoms and results from pulmonary function testing are needed to assess 
the concordance between current clinical guidelines and clinical practice.
Ford et al. Page 6













In conclusion, the percentage of office visits by patients with COPD that resulted in a 
prescription for medications used to treat COPD almost doubled from 1999 to 2010. This 
growth in the rate of prescriptions was led by increases in prescriptions for SABAs, LABAs 
plus ICSs, and tiotropium. Our results suggest that recommendations regarding 
pharmacologic management of patients with COPD are increasingly being adopted by 
physicians.
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Unadjusted percentage (95% standard error) of patients with chronic obstructive pulmonary 
disease aged ≥40 years who were prescribed major groups of medications used to treat 
chronic obstructive pulmonary disease, by year, National Ambulatory Medical Care Survey 
1999–2010.
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Percentage (95% confidence interval) of office visits among patients aged ≥40 years with 
chronic obstructive pulmonary disease listing respiratory symptoms as one of three reasons 
for the visit, by gender and year, National Ambulatory Medical Care Survey 1999–2010.
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Table 1
Medications used in the treatment of chronic obstructive pulmonary disease and groupings of medications 
used in this study’s analyses
Broader grouping Grouping by class Medications
Short-acting agents Short-acting beta-2 agonists (SABA) Albuterol, epinephrine, fenoterol, isoproterenol, isoetharine, levalbuterol, 
metaprotenerol, pirbuterol, terbutaline
Short-acting anticholinergic agent Ipratropium
Combinations of short-acting agents Albuterol/ipratropium, fenoterol/ipratropium
Methylxanthines Aminophylline, dyphylline, theophylline
Any short-acting agent Albuterol, epinephrine, fenoterol, isoproterenol, isoetharine, levalbuterol, 
metaprotenerol, pirbuterol, terbutaline, ipratropium, albuterol/ipratropium, 
fenoterol/ipratropium, aminophylline, dyphylline, theophylline
Long-acting agents Long-acting beta-2 agonists (LABA) 
prescribed as single products
Arformoterol, formoterol, salmeterol
Inhaled corticosteroids (ICS) 
prescribed as single products
Beclomethasone, budenoside, ciclesonide, flunisolide, fluticasone, 
triamcinolone
Combinations of LABAs and ICS Formoterol/budesonide, formoterol/mometasone, salmeterol/fluticasone
Any long-acting beta-2 agonists Arformoterol, formoterol, salmeterol, formoterol/budesonide, formoterol/
mometasone, salmeterol/fluticasone
Any inhaled corticosteroids Beclomethasone, budenoside, ciclesonide, flunisolide, fluticasone, 
triamcinolone, formoterol/budesonide, formoterol/mometasone, salmeterol/
fluticasone
Long-acting anticholinergic agent Tiotropium
Any agent All of above
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